IVD is an important segment in the global healthcare industry
By Nitin Srivastava
Our country is one of the most populated countries in the world and among rapidly developing countries In Vitro Diagnostic (IVD), India leads the emerging nations and follows only the populous, developed economy markets of the US, western European countries, Japan and China. The country and its healthcare system are confronted by challenges shared by the developing countries, as well as rising rates of diabetes, cardiovascular disease, and the diseases of aging.
IVD is an important segment in the global healthcare industry. The marketplace is witnessing rapid growth fueled by technological advancements, better diagnostic tools, improved treatment monitoring, and increased availability of over-the-counter tests. But there are challenges to the growth of the IVD market.
IVD market is divided into may segments like: molecular assays, clinical chemistry and ‘core lab’ markets, point-of-care testing, microbiology and virology by test type, blood banking, tissue-based testing – histology and cytology, infectious disease immunoassay testing, haematology, molecular tests in infectious diseases, coagulation, sequencing and flow cytometry.
The development of IVD product choices has been a boon for medical care, it also puts a great deal of pressure on physicians to make the right choices and for payers to pay for new technologies that may still be unproven. Healthcare organisations have developed strict cost/performance and care guideline directives.
The demand for diagnostic tests in all the major markets is driven by aging populations and increased incidence of conditions such as cancer, diabetes, cardiovascular disease, arthritis and obesity. In light of the demand for these tests, they have been reformulated for automated analysers featured with new and latest technology where the cost per test is traditionally low and reporting time is also very low.
An automated IVD device reduces the analytical errors and gives more precise and accurate results. The automation decreases the HR to run the more complex new set of molecular and histological tests and immunoassays. Therefore, there has been a proliferation of test and lab automation tools launched that remove precious human resources from mundane pre-analytical and sample-tracking tasks to make time for more sophisticated ones. This phenomenon was once thought to be the purview of core lab biochemistry and immunoassays but automation is becoming a common feature hematology, blood banking, microbiology and histology.